Sacubitril/valsartan decreases plasma NT-proBNP in HF patients with preserved ejection fraction: JAMA
Germany: Sacubitril/valsartan significantly decreased plasma NT-proBNP levels at 12 weeks compared with standard medical therapies in patients with heart failure and left ventricular ejection factor of higher than 40%, shows a recent study. However, sacubitril/valsartan did not improve submaximal exercise capacity at 24 weeks. The study was published in the Journal of the American Medical Association (JAMA) on November 16, 2021.
More than 50% of all patients with heart failure have preserved or mildly reduced left ventricular ejection fraction (LVEF >40%) which is related to substantial mortality and morbidity. There is not much evidence on the benefits of sacubitril/valsartan vs broader renin-angiotensin system inhibitor background therapy on 6-minute walk distance, surrogate outcome markers, and quality of life in patients with heart failure and mildly reduced or preserved LVEF of more than 40%.
Against the above background, Burkert Pieske, Charité University Medicine, Campus Virchow Klinikum, Berlin, Germany, and colleagues aimed to the effect of sacubitril/valsartan on N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, 6-minute walk distance, and quality of life compared with background medication–based individualized comparators in patients with chronic heart failure and LVEF of more than 40% in PARALLAX Randomized Clinical Trial -- a 24-week, randomized, double-blind, parallel-group clinical trial (August 2017-October 2019).
Of 4632 patients screened at 396 centers in 32 countries, 2572 patients with heart failure, LVEF of more than 40%, elevated NT-proBNP levels, structural heart disease, and reduced quality of life were enrolled (last follow-up, October 28, 2019).
Patients were randomized in the ratio of 1:1 to receive either sacubitril/valsartan (n = 1286) or background medication–based individualized comparator (n = 1286), ie, enalapril, valsartan, or placebo stratified by prior use of a renin-angiotensin system inhibitor.
Primary endpoints were change from baseline in plasma NT-proBNP level at week 12 and in the 6-minute walk distance at week 24.
At baseline, the median NT-proBNP levels were 786 pg/mL in the sacubitril/valsartan group and 760 pg/mL in the comparator group.
Following were the study's key findings:
- After 12 weeks, patients in the sacubitril/valsartan group (adjusted geometric mean ratio to baseline, 0.82 pg/mL) had a significantly greater reduction in NT-proBNP levels than did those in the comparator group (adjusted geometric mean ratio to baseline, 0.98 pg/mL) with an adjusted geometric mean ratio of 0.84.
- At week 24, there was no significant between-group difference in median change from baseline in the 6-minute walk distance with an increase of 9.7 m vs 12.2 m.
- There was no significant between-group difference in the mean change in the Kansas City Cardiomyopathy Questionnaire clinical summary score (12.3 vs 11.8) or improvement in NYHA class (23.6% vs 24.0% of patients).
- The most frequent adverse events in the sacubitril/valsartan group vs the comparator group were hypotension (14.1% vs 5.5%), albuminuria (12.3% vs 7.6%), and hyperkalemia (11.6% vs 10.9%).
"Compared with standard medical therapies, sacubitril/valsartan resulted in a significantly greater decrease in plasma N-terminal pro–brain natriuretic peptide at 12 weeks but did not significantly improve 6-minute walk distance at 24 weeks," wrote the authors. "Further research is warranted to evaluate potential clinical benefits of sacubitril/valsartan in these patients."
Reference:
Pieske B, Wachter R, Shah SJ, et al. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure andPreserved Ejection Fraction: The PARALLAX Randomized Clinical Trial. JAMA. 2021;326(19):1919–1929. doi:10.1001/jama.2021.18463
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.